Lipoprotein(a) Induces Human Aortic Valve Interstitial Cell Calcification

Area of Science:

• Cardiovascular Biology
• Biochemistry
• Translational Medicine

Background:

• Aortic valve calcification is a significant contributor to cardiovascular disease.
• The role of Lipoprotein(a) (Lp(a)) in this process is not fully elucidated.
• Understanding the molecular mechanisms of Lp(a)-induced calcification is crucial for developing new therapies.

Purpose of the Study:

• To investigate the causal role of Lipoprotein(a) (Lp(a)) in aortic valve calcification.
• To identify the molecular pathways involved in Lp(a)-mediated calcification of human aortic valve interstitial cells.
• To explore potential therapeutic targets for aortic valve calcification.

Main Methods:

• Assessed the effects of Lp(a) on various cellular processes including alkaline phosphatase activity, phosphate release, calcium deposition, and apoptosis in human aortic valve interstitial cells.
• Examined the expression of chondro-osteogenic mediators, SOX9, and matrix Gla protein.
• Investigated the impact of inhibiting MAPK38 and GSK3β signaling pathways on Lp(a)-induced calcification.
• Detected Lp(a) and E06 immunoreactivity in diseased human aortic valves.

Main Results:

• Lp(a) significantly increased alkaline phosphatase activity, phosphate release, calcium deposition, hydroxyapatite formation, cell apoptosis, and matrix vesicle formation.
• Lp(a) elevated chondro-osteogenic mediator expression while decreasing SOX9 and matrix Gla protein levels.
• Inhibition of MAPK38 and GSK3β pathways markedly reduced Lp(a)-induced calcification.
• Lp(a) and E06 were abundantly present in diseased human aortic valves.

Conclusions:

• Lipoprotein(a) plays a causal role in the development of aortic valve calcification.
• Specific signaling pathways (MAPK38, GSK3β) are critical mediators of Lp(a)-induced calcification.
• Targeting the Lp(a) pathway offers a promising novel therapeutic strategy for managing aortic valve calcification.